If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.50
Bid: 45.00
Ask: 46.00
Change: 2.50 (5.81%)
Spread: 1.00 (2.222%)
Open: 43.10
High: 45.75
Low: 43.10
Prev. Close: 43.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

Tue, 05th Mar 2024 17:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

STV Group PLC - Glasgow-based broadcaster - Revenue grows 22% to GBP168.4 million in 2023 from GBP137.8 million a year prior. Total advertising revenue drops 12% to GBP97.3 million from GBP110.0 million. Adjusted pretax profit was GBP9.5 million for the year, down from GBP24.1 million in 2022. STV's dividend was flat for the year at 11.3p per share, after a final dividend of 7.4p. STV has secured GBP87 million in future revenue as at March, GBP30 million a head of the same time a year ago, and the company is encouraged by the "resilience" shown by the advertising market in the year so far. Chief Executive Officer Simon Pitts says: "Our overall financial performance was impacted by weak linear advertising and cost inflation, as expected and related to the challenging UK macro environment, although the start of 2024 has been more encouraging."

----------

Avacta Group PLC- Wetherby, England-based life sciences company specialising in oncology treatments - Set to issue 10.9 million new shares at a price of 50p each following its February retail offer. This remains subject to shareholder approval at the company's annual general meeting on March 18. The REX offer received total applications in excess of the GBP6.8 million limit. The company decided to limit the offer to existing Avacta retail shareholders, and expects a total of GBP5.4 million to be raised from the offer. The company says the proceeds will be used to support the continued clinical development of AVA6000, the company's signature treatment capable of targeting a chemotherapy to the tumour while sparing healthy tissue.

----------

Argo Blockchain PLC - London-based cryptocurrency miner - Enters into agreement for sale of Mirabel, Quebec data centre for a total consideration of USD6.1 million. The proceeds from the sale will be used to repay the facility's outstanding mortgage in full, and the remainder used to pay debts owned to Galaxy Digital Holdings Ltd, an asset manager and trade advisor specialising in digital assets. As of February 29, the Galaxy debt stands at USD14.0 million. The company is in the process of moving mining machines out of the Mirabel facility, and expects the transaction to close by the end of March.

----------

Harland & Wolff Group Holdings PLC - London-based fabrication company, which serves the maritime and offshore industries - Says it has been awarded preferred bidder status for the Falkland Islands Port Replacement Project by the Falkland Islands Government. H&W believes this contract could generate total revenues between GBP100 and GBP120 million over a two-year period, with works on the project expected to commence this year.

----------

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell-therapy company - Updates annual guidance, expecting 2024 revenue of around GBP126 million to GBP134 million. Guidance for the 2023 full-year remains unchanged, with group revenue expected to be around GBP90 million. The group is expecting a loss before interest, tax, depreciation and amortisation for 2023, but is targeting break-even operating Ebitda by the end of 2024.

----------

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
15 Dec 2021 11:56

Avacta confirms lateral flow tests can detect Omicron variant

Avacta confirms lateral flow tests can detect Omicron variant

Read more
15 Dec 2021 08:24

Avacta antigen lateral flow test shown to detect Omicron

(Sharecast News) - Aim-listed Avacta said on Wednesday that its AffiDX® antigen lateral flow test has been shown to detect the Omicron variant of the SARS-CoV-2 virus in clinical samples.

Read more
29 Nov 2021 11:07

IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US

IN BRIEF: Avacta gets FDA nod to expand cancer drug trial into US

Read more
29 Nov 2021 10:38

FDA gives Avacta the go-ahead for US chemotherapy trials

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Monday that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for its chemotherapy drug 'AVA6000'.

Read more
2 Nov 2021 11:25

Avacta and Novacyt await UK regulatory approval for Covid-19 tests

Avacta and Novacyt await UK regulatory approval for Covid-19 tests

Read more
2 Nov 2021 10:21

Avacta suspends UK Covid test sales ahead of new approval

(Sharecast News) - Avacta said on Tuesday that it has suspended sales of its AffiDX Covid latest flow rapid antigen tests in the UK while it awaits new approval.

Read more
30 Sep 2021 11:14

Avacta hails "transformative" first half despite widening loss

Avacta hails "transformative" first half despite widening loss

Read more
30 Sep 2021 09:27

Avacta losses widen as development spend increases

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group reported cash and short-term deposits of £37m at the end of its first half on Thursday, down from £54.5m a year ago and £47.9m at the start of the period.

Read more
29 Sep 2021 10:32

Avacta sees pre-clinical development milestone in LG Chem partnership

Avacta sees pre-clinical development milestone in LG Chem partnership

Read more
29 Sep 2021 09:26

Avacta gets undisclosed milestone payment from LG Chem

(Sharecast News) - Clinical-stage biopharmaceutical company Avacta Group announced on Wednesday that a preclinical development milestone has been achieved in its multi-target therapeutics partnership with South Korea's LG Chem Life Sciences, triggering an undisclosed milestone payment.

Read more
23 Sep 2021 15:59

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
2 Sep 2021 11:50

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

IN BRIEF: Avacta hires oncology drug developer as therapeutics CSO

Read more
18 Aug 2021 14:26

IN BRIEF: Avacta hires cancer doctor Mark Goldberg for board

IN BRIEF: Avacta hires cancer doctor Mark Goldberg for board

Read more
11 Aug 2021 11:29

Avacta doses first patient in chemotherapy medication trial

Avacta doses first patient in chemotherapy medication trial

Read more
11 Aug 2021 10:00

First patient dosed in Avacta's 'AVA6000' trial

(Sharecast News) - Clinical-stage oncology drug company Avacta Group announced on Wednesday that the first patient has been dosed in its phase 1 multicentre trial evaluating 'AVA6000', which it described as a "novel pro-drug" of 'doxorubicin', and its first therapeutic product based on the proprietary 'preCISION' technology.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.